Bulk Inquiry
AZ 628
- Soluble in DMSO
- MF: C27H25N5O2
- MW: 451.52
Description
AZ 628 is a selective RAF kinase inhibitor with reported IC50 values of approximately 30 nM for BRAF V600E and wild-type CRAF.
RAF kinases connect RAS activation to MEK/ERK signaling and are frequent drivers of oncogenic MAPK pathway activation. AZ 628 is useful for studying RAF inhibition, BRAF-mutant tumor biology and RAF-dependent feedback within the MAPK cascade.
Key Features
- Selective inhibitor of RAF kinases
- Reported IC50 around 30 nM for BRAF V600E and CRAF
- Strong selectivity for RAF kinases in broad kinase panels
- Tool for investigating RAF-dependent MAPK signaling
Applications
- BRAF and CRAF kinase assays
- Melanoma and MAPK-driven cancer models
- RAF inhibitor mechanism studies
- ERK pathway feedback research
More Information
| Parent CAS No. | 878739-06-1 |
|---|---|
| Chemical Name | 3-(Cyano-dimethyl-methyl)-N-[4-methyl-3-(3-methyl-4-oxo-3,4-dihydro-quinazolin-6-ylamino)-phenyl]-benzamide |
| SMILES | CC(C#N)(C1=CC=CC(=C1)C(=O)NC1=CC(=C(C)C=C1)NC1=CC2=C(C=C1)N=CN(C)C2=O)C |
| MFCD | MFCD17392577 |
| InChi | InChI=1S/C27H25N5O2/c1-17-8-9-21(31-25(33)18-6-5-7-19(12-18)27(2,3)15-28)14-24(17)30-20-10-11-23-22(13-20)26(34)32(4)16-29-23/h5-14,16,30H,1-4H3,(H,31,33) |
| InChiKey | ZGBGPEDJXCYQPH-UHFFFAOYSA-N |
| CID | 11676786 |
| Short Description | C-RAF inhibitor |
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1357 | SD 169 |
From $66.00 |
| 1358 | BIRB 796 |
From $71.50 |
| 1363 | SB 203580 |
From $104.50 |
| 1364 | SB 202190 |
From $104.50 |
| 1365 | PD169316 |
From $104.50 |
| 1397 | Sorafenib tosylate |
From $77.00 |
| 1459 | GDC 0879 |
From $77.00 |
| 1474 | PLX 4720 |
From $55.00 |
| 1624 | PLX 4032 |
From $66.00 |
| 1984 | GW 5074 |
From $93.50 |
| 2438 | Cuspin-1 |
From $104.50 |
| 2504 | SB 590885 |
From $104.50 |
| 2590 | Locostatin |
From $66.00 |
| 2817 | RAF709 |
From $132.00 |
| 3067 | Belvarafenib |
From $126.50 |
| 3351 | Sorafenib |
From $66.00 |
| 3556 | LXH254 |
From $198.00 |
| 3862 | BGB-283 |
From Inquiry |
| 4033 | TAK-632 |
From Inquiry |
| 4146 | LGX818 |
From Inquiry |
